Literature DB >> 3015556

Plasma immunoreactive proopiomelanocortin peptides and cortisol in normal dogs and dogs with Addison's disease and Cushing's syndrome: basal concentrations.

M E Peterson, D N Orth, N S Halmi, A C Zielinski, D R Davis, F T Chavez, W D Drucker.   

Abstract

We measured basal plasma concentrations of the immunoreactive (IR) proopiomelanocortin (POMC)-derived peptides ACTH, beta-lipotropin (beta LPH), beta-endorphin (beta END), and alpha MSH in 160 normal dogs, 32 dogs with Addison's disease, 42 dogs with adrenocortical tumors causing Cushing's syndrome, and 169 dogs with pituitary-dependent Cushing's disease. In normal dogs, plasma IR-POMC peptide levels were similar to those in man, except that IR-alpha MSH, a pars intermedia POMC product, was readily detected. In Addisonian dogs, plasma cortisol was decreased, and the IR-POMC peptides were increased, except for IR-alpha MSH, which was normal. In 7 Addisonian dogs given dexamethasone, elevated plasma IR-ACTH, beta LPH, and beta END levels fell dramatically. In dogs with Cushing's syndrome due to adrenal tumors, plasma IR-ACTH, beta LPH, and beta END were decreased, and cortisol was increased, but IR-alpha MSH was normal. Dogs with Cushing's disease due to pars distalis tumors had elevated plasma IR-ACTH, beta LPH, beta END, and cortisol, but normal IR-alpha MSH; their plasma cortisol was suppressed by dexamethasone. There appeared to be 2 types of pars intermedia tumors causing Cushing's disease: 1 dexamethasone nonsuppressible and with disproportionately high plasma IR-alpha MSH levels, the other relatively dexamethasone suppressible and with normal to slightly elevated IR-alpha MSH levels. These 2 pars intermedia tumor types may arise from 2 distinct normal canine pars intermedia cell types. Canine Cushing's disease may provide a useful model for variants of the disorder in man.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015556     DOI: 10.1210/endo-119-2-720

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Absence of detectable immunoreactive alpha melanocyte stimulating hormone in plasma in various types of Cushing's disease.

Authors:  R J Croughs; J H Thijssen; J A Mol
Journal:  J Endocrinol Invest       Date:  1991-03       Impact factor: 4.256

2.  Corticotroph (Basophil) invasion of the pars nervosa in the human pituitary: Localization of proopiomelanocortin peptides, galanin and peptidylglycine α-amidating monooxygenase-like immunoreactivities.

Authors:  Ricardo V Lloyd; Constance J D'Amato; Michelle T Thiny; Long Jin; Samuel P Hicks; William F Chandler
Journal:  Endocr Pathol       Date:  1993-06       Impact factor: 3.943

Review 3.  Diagnosis of canine spontaneous hypoadrenocorticism.

Authors:  Pedro J Guzmán Ramos; Michael Bennaim; Robert E Shiel; Carmel T Mooney
Journal:  Canine Med Genet       Date:  2022-05-03

4.  ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing's syndrome.

Authors:  Daniel K Langlois; Michele C Fritz; William D Schall; N Bari Olivier; Rebecca C Smedley; Paul G Pearson; Marc B Bailie; Stephen W Hunt
Journal:  BMC Endocr Disord       Date:  2018-05-02       Impact factor: 2.763

5.  TRH-induced secretion of adrenocorticotropin and cortisol in dogs with pituitary-dependent hypercortisolism.

Authors:  Tera Pijnacker; Marieke Knies; Sara Galac; Karin Sanders; Jan A Mol; Hans S Kooistra
Journal:  Vet Q       Date:  2018-12       Impact factor: 3.320

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.